Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
As of today, Biogen(BIIB) shares are valued at $201.18. The company's market cap stands at 29.49B, with a P/E ratio of 16.90.
As of 2026-02-06, Biogen(BIIB) stock has fluctuated between $184.60 and $202.41. The current price stands at $201.18, placing the stock +9.0% above today's low and -0.6% off the high.
The Biogen(BIIB)'s current trading volume is 3.38M, compared to an average daily volume of 1.45M.
During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $202.41 at its peak.
During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $202.41 at its peak.
BIIB News
Biogen Inc. ((BIIB)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and...
BMO Capital analyst Evan Seigerman raised the firm’s price target on Biogen (BIIB) to $196 from $165 and keeps a Market Perform rating on the shares following Q...
The Alzheimer's drug maker reported revenues of $2.28 billion, beating the consensus of $2.20 billion, down 7% on a reported and constant currency basis. Drugs...
Analyst ratings
51%
of 37 ratingsMore BIIB News
Image source: The Motley Fool. Feb. 6, 2026, 8:30 a.m. ET Call participants President and Chief Executive Officer — Christopher Viehbacher Head of Development...
Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments. BRIAN SNYDER/REUTERS Biogen BIIB...
Despite recording better-than-expected Q4 2025 financials, Biogen (BIIB) on Friday projected a mid-single-digit percentage decline in revenue for 2026 compared...
(RTTNews) - Biotechnology company Biogen, Inc. (BIIB) reported Friday a net loss attributable to the company for the fourth quarter of $48.9 million or $0.33 pe...
For full year 2026 as compared to full year 2025, Biogen (BIIB) expects the gross margin percentage, and combined Non-GAAP R&D expense and Non-GAAP SG&A expense...
Technology How One Drug Heavy-Lifted Biogen's Fourth-Quarter Beat Licensing Biogen (BIIB) narrowly topped Wall Street's fourth-quarter expectations Friday, than...
(RTTNews) - Biogen Inc. (BIIB) will host a conference call at 8:30 AM ET on February 6, 2026, to discuss Q4 25 earnings results. To access the live webcast, lo...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.